Biocryst Pharmaceuticals Inc
NASDAQ: BCRX
$7.27
-$0.33 (-4.3%)
Closing Price on November 25, 2024
BCRX Articles
The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola drugs might not be a cure-all for patients.
Published:
Tekmira Pharmaceuticals downgrade also drags down Sarepta Therapeutics and BioCryst Pharmaceuticals.
Published:
With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides of the Ebola story.
Published:
News has hit of the first confirmed Ebola case in the United States. Companies involved in potential drugs for Ebola have seen their shares pop.
Published:
ThinkstockAfter being absolutely rocked back in the spring, the biotech sector has bounced back smartly. Even a bubble comment from the head of the Federal Reserve Janet Yellen didn’t stop the...
Published:
Jon OggStocks turned green on Friday morning on hopes out of Russia, but the markets have remained at risk. Now that investors have an opportunity to look for stocks that have pulled back, 24/7 Wall...
Published:
ThinkstockThe world is dealing with Ebola outbreaks and scares again. We are also in the midst of debates as to whether two Americans who contracted Ebola in Africa should have been brought back for...
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations for Monday, June 23, 2014. They include AMD, Dish Network, Facebook, Nordstrom and SunPower.
Published:
Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at one stage or another and that could be the next takeover targets.
Published:
BioCryst Pharmaceuticals broke higher Tuesday morning, following the company's announcement that its oral drug for hereditary angioedema met objectives established for its Phase 2a clinical trial.
Published:
Last Updated:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, January 28, 2014. They include Apple, Dow Chemical and Sally Beauty.
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, January 27, 2014. They include Cisco Systems, Lululemon Athletica, Nokia, Peabody Energy...
Published:
Jon OggEarnings season may be winding down and the stock market may be close to all-time highs, but now traders and investors alike have to be considering how to position their portfolios and...
Published:
ThinkstockViroPharma Inc. (NASDAQ: VPHM) has become the latest and greatest biotech buyout candidate after a report of it being a buyout candidate surfaced last week. We saw some 11 million shares...
Published:
Jon OggNow that stocks have pulled back and interest rates have risen, investors are looking for more guidance on which stocks they should still buy and which stocks they should sell or avoid. 24/7...
Published: